Dr. Ron Witteles and Dr. C. Michael Gibson discuss: Atrial fibrillation, arrythmias, and other cardiac manifestations in patients with ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Clinical Trial Results
Search
Dr. Richard Cheng and Dr. C. Michael Gibson discuss: Presentation, screening, and disease progression of variant ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc
Dr. James Ampadu and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. Richard Wright and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc
Dr. Joshua Mitchell and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. M. Trejeeve Martyn and Dr. C. Michael Gibson discuss: The importance of early screening, diagnosis, and treatment for ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. Adam Castano and Dr. C. Michael Gibson discuss: ACT-EARLY, a Phase 3 Study – Clinical Trial Results
Disclosures: Sponsored by BridgeBio Pharma, Inc
#ACC2025 Obesity Wrap Up:
Dr. Danielle Belardo and Dr. C. Michael Gibson discuss the PRAGUE-25 trial (catheter ablation vs. antiarrhythmics with weight management and […]